The Phase I trial results, recently published in the esteemed journal Nature Medicine, revealed an extraordinary overall response rate of 92.9% with a complete response rate hitting 66.7%. These figures were derived from a cohort of 42 heavily pretreated patients, meaning they had undergone numerous prior therapies and were still persistent in their illness. Such promising statistics signal not only a potential new direction for treating refractory lymphomas but also the flexibility of this strategy to be adapted for broader types of cancer as research progresses.

Principal investigator Dr. Yago Nieto, who serves as a professor in the Stem Cell Transplantation & Cellular Therapy department at MD Anderson, articulated the significance of these findings. He underscores the rapid and potent responses observed in patients treated with the AFM13-NK cells, affirming the ongoing evaluations of the therapy’s effectiveness in tackling challenging malignancies. His enthusiasm points to a larger ambition that this therapeutic innovation may serve either as a curative measure for some patients or act as a crucial bridge to potentially life-saving stem cell transplants.

The methodology behind this trial hinges on the unique characteristics of Affimed’s AFM13 bispecific antibody. This engineered molecule is specifically designed to bind with CD16A on NK cells and detects CD30 on malignant lymphoma cells. With this pre-complexing approach, AFM13-NK cells are empowered to better target and obliterate CD30-positive lymphoma cells. The process involves initially activating the NK cells using cytokines, expanding them in conjunction with artificial antigen-presenting cells, and then combining them with the AFM13 antibody before infusing them into the patient’s bloodstream.

The laboratory contributions of Dr. Katy Rezvani, who holds the Sally Cooper Murray Endowed Chair in Cancer Research, are fundamental to the development of this cell therapy. As the vice president of the Institute for Cell Therapy Discovery & Innovation at MD Anderson, Dr. Rezvani has been pivotal in advancing cell therapies, highlighting a concerted effort towards developing impactful innovations for multiple medical conditions.

The trial specifically included 37 adult patients with known CD30-positive Hodgkin lymphoma and an additional five with T-cell lymphoma. Notably, all participants had been heavily pretreated and had demonstrated non-responsiveness to established therapies, such as brentuximab vedotin and the anti-PD1 immune checkpoint inhibitors. The trial participants had a median age of 43 years, with an alarming median of seven prior lines of treatment, showcasing the dire circumstances faced by these patients when entering the study.

The trial involved administering a series of two to four cycles of chemotherapy, subsequently followed by infusions of the AFM13-NK cells at three different dose levels across three weekly sessions. Each treatment cycle concluded with a rigorous evaluation of each participant’s treatment response on day 28, along with structured follow-ups every three months to monitor their ongoing health status.

The results were not just numeric; they painted a picture of hope. The overall response rate (ORR) and complete response (CR) rates among study participants stood at an impressive 92.9% and 66.7%, respectively. Among those diagnosed with Hodgkin lymphoma, the statistics climbed even higher, with ORR and CR reaching 97.3% and 73%. Such results, particularly when benchmarked against this heavily pretreated patient pool, underscore the noteworthy effectiveness of the AFM13-NK cell therapy in these challenging cases.

Over a median follow-up period of 20 months, the two-year event-free survival (EFS) and overall survival (OS) rates for participants were reported as 26.2% and 76.2%, respectively. Given the refractory nature of the tumors exhibited by participants, these survival rates are particularly encouraging, reinforcing the therapy’s potential impact on long-term patient outcomes.

Despite the complexity of the treatment, patients tolerated the AFM13-NK cell therapy well, with no documented instances of cytokine release syndrome, neurotoxicity associated with immune cells, or graft-versus-host disease, which are common complications in such treatments. The only adverse event noted was a Grade 2 infusion-related reaction, suggesting the treatment’s safety profile is remarkably favorable compared to other emerging therapies.

Cord blood units selected for each treatment cycle were sourced from the MD Anderson Cancer Center Cord Blood Bank, adhering to strict criteria established for optimal donor cell characteristics. This attention to donor cell quality ensured that NK cells reached peak levels in patient blood one day following infusion, with a notable persistence of healthy donor cells up to three weeks, effectively enabling them to migrate towards tumor sites.

In conclusion, the trial demonstrated a promising safety profile and an encouraging level of efficacy for AFM13-NK cells specifically in patients dealing with refractory CD30-positive Hodgkin lymphoma. Dr. Yago Nieto’s statement reflects a growing optimism about the potential applications of this cell therapy methodology, suggesting it could not only revolutionize treatment protocols for Hodgkin lymphoma but also lay the groundwork for future research involving NK cells used in conjunction with bispecific engagers for various malignancies.

The research was supported by Affimed, with additional funding from MD Anderson and contributions from the National Institutes of Health. With the trial continuing to gather insights and data, medical professionals remain hopeful about translating these findings into widespread clinical practice, ultimately enriching the therapeutic options available for patients battling difficult-to-treat cancers.

Subject of Research: Novel cell therapy using NK cells for refractory CD30-positive lymphomas
Article Title: Innovative Cell Therapy Offers Hope for Refractory CD30-Positive Lymphoma Patients
News Publication Date: [Not Provided]
Web References: [Not Provided]
References: [Not Provided]
Image Credits: [Not Provided]

Keywords: Natural killer cells, cancer patients, Hodgkin lymphoma, CD30, cell therapy, bispecific antibodies.

For years, the quest to eradicate cancer cells without causing harm to normal surrounding cells has been a fundamental aim of cancer therapies. Conventional methods often struggle to distinguish between cancerous and healthy cells, especially in diseases like AML where specific tumor antigens are difficult to identify. Despite significant advancements in allo-HCT, relapse remains a major challenge for many AML patients, underscoring the urgent need for innovative treatment methodologies.

In the study led by The University of Osaka, the research team embarked on an investigative journey to unearth tumor-specific antigens that could be targeted without affecting normal cells. They employed a systematic approach that had previously yielded success in multiple myeloma research where monoclonal antibodies were screened to identify those specifically reactive to cancer cells while sparing normal hematopoietic cells. By adapting this strategic methodology, the researchers aimed to pinpoint AML-specific antigens that could potentially serve as effective targets for CAR-based therapies.

The screening process began with the examination of thousands of monoclonal antibodies designed to bind to AML cells. Through a rigorous evaluation procedure, the team successfully narrowed the focus down to 32 distinct mAbs, each uniquely binding to AML cells. Among these, the antibody designated as KG2032 demonstrated a remarkable specificity by binding to AML cells in over half of the patient samples analyzed. Further investigation revealed that KG2032 binds preferentially to the HLA-DRB1 molecule, a promising discovery that highlights the therapeutic potential of targeting HLA-DRB1 in the context of AML.

In an intriguing twist of immunological specificity, the research showed that KG2032 is not just a general AML target but interacts with a specific subset of the HLA-DRB1 molecule. Specifically, this subset possesses an amino acid different from aspartic acid at the 86th position of the protein structure. This specificity implies that KG2032 can effectively target AML cells in individuals who possess this particular amino acid variant, while the corresponding donor from whom they receive stem cells through allo-HCT does not. This unique compatibility underscores the potential for developing a personalized therapeutic strategy tailored to individual patient profiles.

The implications of identifying HLA-DRB1 as a therapeutic target cannot be overstated, especially for patients who experience relapse post-allo-HCT. To validate their findings, the research team engineered KG2032 CAR T cells that lacked the reactive HLA-DRB1 allele and conducted both in vitro cell culture experiments and in vivo tests using mouse models. The results were striking; the CAR T cells exhibited potent and specific anti-AML activity, demonstrating significant efficacy without showing overt toxicity in the treated mice—a crucial consideration for clinical applicability.

In parallel to the achievements with CAR T cells, the researchers also explored the potential of cord blood-derived CAR NK cells, which were engineered in a similar fashion to produce encouraging outcomes. These findings collectively illustrate a novel therapeutic pathway that could significantly enhance treatment options available to AML patients, particularly in the context of relapse following allo-HCT. With the knowledge that both CAR T and NK cells have demonstrated efficacy in targeting HLA-DRB1-expressing AML cells, the research team is now poised to launch clinical trials to further evaluate the safety and effectiveness of these approaches in human patients.

Emerging from this study is a sense of optimism regarding the future of cancer treatments, particularly for individuals grappling with the challenges posed by relapsed AML. The innovative strategies developed in this research could transcend conventional treatment limitations, offering a tailored therapeutic intervention that effectively spares normal cells while targeting malignant ones. This paradigm shift in cancer therapy not only promises to improve patient outcomes but may also inspire further explorations into the intricacies of immunotherapy for various malignancies.

As the scientific community eagerly anticipates the outcomes of forthcoming clinical trials, the groundbreaking research from The University of Osaka stands as a testament to the power of interdisciplinary collaboration and innovative thinking in addressing the urgent challenges presented by aggressive cancers like AML. The journey from laboratory discoveries to clinical applications remains fraught with challenges, but the relentless pursuit of solutions in combating cancer continues to hold vast potential for transformative impact on patient care and survival.

In summary, the innovative CAR T and NK cell therapies targeting HLA-DRB1 present a beacon of hope for AML patients, particularly those who have faced relapse following allo-HCT. This pioneering research underscores the importance of specific targeting in cancer therapies and sets the stage for a new era in the treatment of hematological malignancies. As the research unfolds, the potential for personalized medicine becomes increasingly tangible, paving the way towards a future where effective and targeted therapies can improve survival rates and enrich the quality of life for patients afflicted with malignancies.

Subject of Research: Cells
Article Title: CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant
News Publication Date: 24-Mar-2025
Web References: N/A
References: N/A
Image Credits: The University of Osaka

Keywords: Health and medicine, AML, CAR T therapy, NK cells, HLA-DRB1, cancer treatment, immunotherapy, hematological malignancies.